StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Earnings

Lipocine's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$2.30M
+1907.4% on a year earlier
EPS, Q3 FY2026
-$0.08
-$0.59 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Lipocine's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026during market hours$2.30M+1907.4%-$0.08Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open$190.00K-69.5%-$0.32Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open––-$0.52Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$114.57K–-$0.59Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025before the open$622.85K–-$0.41Release
Q4 FY2023ended Dec 31, 2023Mar 7, 2024before the open–––Release
Q4 FY2020ended Dec 31, 2020Jan 25, 2021after the close–––Filing
Q3 FY2017ended Sep 30, 2017Nov 8, 2017before the open–––Filing
Q2 FY2017ended Jun 30, 2017Aug 7, 2017before the open–––Filing
Q1 FY2017ended Mar 31, 2017May 8, 2017before the open–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Lipocine has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Lipocine puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Lipocine filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. News
  4. News
  5. News
  6. News
  7. News
  8. Results
  9. Update
  10. News
  11. News
  12. News
  13. News
  14. News
  15. News

See a number that looks wrong?